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Background: Compared with angiogenesis, arteriogenesis is a distinct process based on the remodeling and maturation of
pre-existing arterioles into large conductance arteries. Therapeutic angiogenesis has been proposed as a potential treatment for
ischemic atherosclerotic diseases. Since a variety of angiogenic factors have been tested with inconsistent so far clinical results,
the challenge remains in identifying the factor(s) that will stimulate functional neovascularization. Thrombin has been
reported to play a pivotal role in the initiation of angiogenesis by regulating and organizing a network of angiogenicmediators.
Also, it was recently demonstrated that thrombin is a potent anti-apoptotic factor for endothelial cells, providing evidence on
a potential role of thrombin in vascular protection and maintenance of vessel integrity. Based on these observations, we
hypothesized that thrombin may promote the development of mature functional blood vessels.
Methods: Seventy-four (n74) rabbits underwent bilateral femoral artery surgical excision. On the 20th postsurgical day
increasing doses of VEGF or bFGF or thrombin were injected in one ischemic limb per rabbit and an equal volume of normal
saline to the contralateral control limbs. Quantification of newly developed collateral vessels (diameter >500 m) was
performed by transauricular intra-arterial subtraction angiography. Computerized quantitative analysis of collateral vessels in
angiography images was based on the concept of multiscale structural tensor. Perfusion analysis of an in vivo dynamic
computed tomography study was performed to investigate hemodynamic recovery of the distal ischemic limbs. Tissue
perfusion analysis was performed with the semiquantitative slope methodology, which focuses on the first-pass arterial phase.
Results: A single administration of thrombin exhibited a dose-dependent increase of arteriogenic outcome. Thrombin at
5000 IU induced a 30.2  7.4% (P < 0.05) increase of total collateral area and length. Both VEGF and bFGF were
without any significant effect at the concentrations used. Functional estimation of limb perfusion showed a statistically
significant increase of blood flow recovery only for thrombin. The semiquantitative slope method perfusion score differed
significantly in the 5000 IU thrombin treated limbs (5.7 0.3 vs 5.0 0.3 in control ischemic limbs; P< .05), and was
not significantly inferior from the score of normal nonoperated limbs (6.5  0.3) suggesting a trend towards
hemodynamic recovery of distal limb perfusion.
Conclusions: In a rabbit hindlimb ischemia model, thrombin promoted the formation of large collateral vessels and
improved the perfusion of distal ischemic tissue. These results provide new insights in understanding the involvement of
thrombin in vascular formation and point to a novel role of thrombin in arteriogenesis. ( J Vasc Surg 2009;49:1000-12.)
Clinical Relevance: Interplay between angiogenic growth factors and vascular maturation mechanisms are essential for the
cascade of reactions involved in arteriogenesis, i.e. development of large conductance collateral vessels that may adequately
compensate for atherosclerotic arterial occlusions. We have shown that thrombin stimulated robust collateral networks in the
ischemic limbs, which was associated with a significant recovery of ischemic tissue perfusion as assessed by in-vivo perfusion
studies. Thismay provide the basis for applications of thrombin and its nonthrombogenic analogs in therapeutic angiogenesis.In clinical practice, some patients with peripheral vas-
cular disease present few or no symptoms despite a signifi-
cant stenosis or even occlusion of a main feeding artery.
This is mostly evident in patients with slowly progressing
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1000vascular occlusions, where an endogenous collateral circu-
lation had sufficient time to develop, bypassing the site of
stenosis and protecting the downstream tissue from isch-
emic injury. On the other hand, in most cases the vascular
lesion progresses too fast or the collateral circulation devel-
ops too slowly and remains insufficient to compensate for
the obstructed artery. In these cases, therapeutic stimula-
tion and acceleration of this natural protective mechanism
has the potential to become an alternative approach to
improve blood supply to compromised tissue. Indeed,
many pharmacologic approaches were used to stimulate the
growth of collateral arteries basedmainly on the knowledge
gained from studying pathologic angiogenesis.1 A variety
of protein-, gene-, and cell-based cytokines and angiogenic
growth factors have been investigated in vitro and in
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ies observed in pathologic angiogenesis is fundamentally
different from the beneficial arteriogenesis (the enlarge-
ment of small pre-existing anastomoses towards large con-
ductance arteries) in arterial occlusive diseases.4 This differ-
ence is likely the explanation of the limited success of first
clinical trials and warrants further investigation of the
mechanisms that regulate the arteriogenic process.
Thrombin, apart from its central role in blood coagu-
lation, exerts a wide range of effects on endothelial cells,
which may contribute to the control of many functions,
including vascular tone, hemostasis, inflammation, and
angiogenesis.5 Thrombin, mainly through proteinase-
activated receptor 1 (PAR1) signalling, stimulates many
vascular cells as well as endothelial cells and regulates the
release, expression, and activation of the majority of angio-
genesis mediators.6 For example, thrombin-induced angio-
genesis in the chick embryo system7 was associated with
upregulation of vascular endothelial growth factor (VEGF)
as well as angiopoietin-2 (Ang-2).8 In line with this, throm-
bin upregulated VEGF9 and Ang-210 in endothelial cells.
Another important effect of thrombin was the potentiation
of mitogenic activity of VEGF on endothelial cells.11 In
addition, thrombin plays a role in promoting angiogenesis
by PAR1-independent mechanisms. It has been demon-
strated that immobilized thrombin functioning directly
through its RGD sequence interacted with 3 and 51
integrins and promoted attachment, migration, and sur-
vival of endothelial cells.12,13 These effects of thrombin
provide a plausible explanation for the angiogenesis par
excellence occurring within thrombi, where thrombin is
trapped, in several pathophysiologic conditions. Further-
more, it was recently shown that soluble thrombin pro-
tected endothelial cells from apoptosis via twomechanisms:
a minor contribution was mediated by PAR1 activation and
a major contribution by interaction with 3 and 51
integrins in which the catalytic site of thrombin is not
necessary.14 The involvement of thrombin in endothelial
cell survival may open new insights on the role of thrombin
in vascular protection and provides evidence for an essential
contribution of thrombin in the establishment and mainte-
nance of vessel wall integrity.
Interplay between pro-angiogenic growth factors and
vascular protectionmechanisms are essential for the cascade
of reactions involved in blood vessel formation and matu-
ration. In this context, the thrombin-mediated arterial pro-
tection together with its potent angiogenic ability may
prove to be useful in the development and maturation of
new large conductance collateral vessels that may compen-
sate for atherosclerotic arterial occlusions and achieve effec-
tive reperfusion of distal ischemic tissue.15,16 We hypothe-
sized that thrombin stimulates arteriogenesis and enhances
hemodynamic recovery of experimental limb ischemia. We
investigated the arteriogenic properties of thrombin in a
rabbit hindlimb ischemia model after bilateral femoral ar-
tery excision, where the formation of functional collateralvessels with vascular stability is essential for the recovery of
ischemic tissues. We have shown that a single administra-
tion of thrombin was able of establishing functional vascu-
lar networks.
MATERIAL AND METHODS
The study included 74 (n  74) New Zealand White
rabbits (male sex, approximately 6-month-old, weight 3.0-
4.0 kgs) that underwent bilateral femoral artery surgical
excision. On the 20th postsurgical day increasing doses of
thrombin or VEGF or bFGF were injected in one ischemic
limb per rabbit and an equal volume of normal saline to the
contralateral control limbs; ie, groups of ischemic controls.
A group of nonoperated subjects (n  6) were also in-
cluded in the study and served as an external control group
of normal rabbit hindlimbs; ie, group of normal controls
(Fig 1).
Animal hindlimb ischemia model and experimental
protocol. The in vivo investigation protocol conformed to
the Guide for the Care and Use of Laboratory Animals
published by the United States National Institutes of
Health (NIH Publication No. 85-23, revised 1996) and
was approved by local University Hospital’s local Scientific
and Ethical Committee. Bilateral hindlimb ischemia was
surgically induced in all rabbits under dissociative anesthe-
sia with an intramuscular injection of ketamine 50 mg/kg
and xylazine 10 mg/kg as described elsewhere.17 Briefly,
animals were placed on a heating pad and an intravenous
Fig 1. Flowchart of experimental protocol. Seventy-four (n 
74) New Zealand White rabbits underwent bilateral femoral artery
surgical excision. On the 20th postsurgical day increasing doses of
thrombin or VEGF or bFGF were injected in one ischemic limb
per rabbit and an equal volume of normal saline to the contralateral
control limbs; ie, groups of ischemic controls. A group of nonop-
erated subjects (n  6) was included in the study as an external
control group of normal rabbit hindlimbs; ie, group of normal
controls. On the 40th postsurgical day imaging and histology was
performed as indicated.normal saline drip (15 mL/h) was administered through a
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limbs were longitudinally incised on the medial thighs.
Incisions extended from the inguinal ligament to just prox-
imal to the patella. The femoral artery and all its major
branches, including the inferior epigastric, deep femoral,
lateral circumflex, and superficial epigastric artery, were
dissected (Fig 2, A and B). The distal external iliac artery
and the aforementioned major branches were ligated. Ex-
perienced veterinary staff closely monitored all rabbits dur-
ing the immediate postoperative period.
Escalating doses of vascular endothelial growth factor
(1 g or 3 g or 10 g VEGF; Chemicon International
Inc, Temecula, Calif) or basic fibroblast growth factor (1
g or 3g or 10g bFGF, Chemicon International Inc) or
bovine thrombin (500 IU or 1500 IU or 5000 IU or
15,000 IU Thrombin-JMI, King Pharmaceuticals, Inc,
Middleton, Wis) were intramuscularly injected in one isch-
emic limb per rabbit, randomly selecting between left and
right (Table). The growth factors were diluted in 1mL of
solution and administered with three separate injections
(0.33 mL per injection, injection points approximately 1.5
cm apart) along the course of the excised femoral artery and
medially to the bone. An equal volume of normal saline
(1mL) was injected in the same way in the contralateral
limb in order to serve as an internal control for each study
group. Injections were performed on the 20th postsurgical
day. The 20-day interval between the surgical excision of
the femoral artery and the injection of the agents was
chosen with respect to quiescence of the endogenous
angiogenesis, which is believed to occur 10 to 20 days
after the induction of acute limb ischemia in the rabbit
model.15,17 It has been shown that although ischemia-
driven capillary sprouting is maximized within 5 days of
femoral artery removal, angiographic collateralization and
improvement of reserve blood flow capacity reach a plateau
after 20 days.15 All animal subjects were then followed up
with morphological and functional in vivo imaging 20 days
after the delivery of the angiogenic stimulant, ie, on the
40th postsurgical day, so as to allow for an equal time
interval for the development and augmentation of new
collateral arteries. The group of normal controls underwent
only the imaging modalities (Fig 1).
Transauricular intra-arterial digital subtraction an-
giography and computerized image postprocessing.
Digital subtraction angiography (DSA) was performed in
the medial thigh of both ischemic hindlimbs in order to
depict the newly developed collateral vessels and obtain an
accurate quantitative score of the arteriogenic outcome
triggered by the administration of the indicated sub-
stances.18-20 Intra-arterial vascular access was established
in all rabbits through a minimally invasive transauricular
route, which obviates major surgery and minimizes sub-
jects’ stress and pain, as recently described.21 Briefly, a
0.018-inch hydrophilic guidewire (V18, Boston Scientific,
Natick, Mass) was advanced in the central auricular artery
under fluoroscopic navigation and a 4F vascular sheath was
inserted in the common carotid artery after serial dilations
of the auricular subcutaneous tract. The rabbit infrarenalabdominal aorta was selectively catheterized with a straight
4F catheter by routine endovascular instruments and ma-
neuvers under fluoroscopic guidance. The tip of the 4F
angiographic catheter was located above the iliac bifurca-
tion in order to simultaneously record DSA images of both
hindlimbs, avoid variations of the animal’s blood pressure
and heart rate, or arterial spasm that could affect DSA
acquisition and eliminate movement artefacts when com-
paring with the control limbs. DSA images were obtained
with the clinical Philips DVI-S angiography unit using the
acquisition protocol of 1 image per second at 40–90 KV.
Nonionic iodinated contrast (Iomeron, 400 mg iodine per
mL, Bracco, Milan, Italy) was infused at a rate of 1 mL/s (5
mL total contrast volume) with an automated angiographic
injector pump. The hindlimbs of the rabbits were positioned
25 cm below the X-ray tube and the focal spot to intensifier
distance was 110 cm. In order to achieve field homogeniza-
tion and increase image quality, an aluminium filter was inter-
posed between the subject and the intensifier.
For postprocessing of DSA images (Fig 2,A and B), we
applied a recently described method for quantitative anal-
ysis of the collateral vessels in angiography images, based on
the concept of multiscale structural tensor.22 Briefly, the
baseline digital angiographic image is initially smoothed by
a 2DGaussian sigma standard deviation. Consequently, the
Hessian matrix, also called structural matrix, is produced by
the second order Gaussian derivatives of the image. A
step-wise multiscale eigen-value analysis of the Hessian
matrix achieves accurate extraction and segmentation of the
vasculature map within the image. A region-of-interest
(ROI) was drawn in the area of the medial thigh to include
the newly developed collaterals (Fig 2, B). The same ROIs
that were used in all limbs in order to reproduce equal
sampling areas and pixel counts were further normalized
against a known standard size (tip of the 4F angiographic
catheter that was positioned in the distal abdominal aorta
and included in the DSA frames; 1F  333 m). The
selected vascular objects were initially measured for their
total vessel area and then for their length, using a skeleton-
ization procedure that collapses vessel diameter to one
pixel. Focusing on the process of arteriogenesis and collat-
eralization, the software segmented and quantified collat-
eral vessels with a diameter greater than 500 m. The
applied software may be found as a free download at
http://stat.med.upatras.gr/JDI.
Functional evaluation with dynamic computed
tomography. In order to noninvasively evaluate the he-
modynamic properties of the evolving revascularization
process and the newly developed arterial networks, we used
the dynamic computed tomography (CT) technology.23-25
We performed a first-pass study at the level of the saphe-
nous artery, 2 cm below the knee joint and distal to the area
of the injected angiogenic factors. On the 40th postsurgical
day anesthetized subjects were placed in the supine position
in a clinical new-generation 16-row CT modality (Light-
speed, GE Medical Systems, Milwaukee, Wis). An initial
scan (scout) of the animals was undertaken to allow local-
ization of the knee articulations, which served as the corre-
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normal rabbits. (a) DSA of the rabbit hindlimbs. The normal vascular anatomy of the abdominal aorta (1), the internal
iliac artery (2), the femoral artery (3), the profunda femoris (4), and the saphenous artery below the knee (5) are shown.
Surgical ischemia is invoked bilaterally by excising the femoral artery (3) and ligating all its branches (vessels within the
circles). Hemodynamic functional analysis was performed in the indicated region of tissue (area within the rectangular
box). (b) Image analysis and vessel enhancement after sequential filtering and computerized postprocessing. (c) Final
image after isolation of the large vessels (d  500 m), which permits quantitative measurements of the area and the
length of the segmented vessels. (d) Skeletonization of segmented large vessels, which is superimposed on the original
DSA image. B, Representative quantitative angiography in thrombin-treated ischemic rabbits. (a) Final DSA angio-
gram 20 days after intramuscular injection of 5000 IU of thrombin in the right hindlimb of the rabbit. Left (L) foot
served as the control foot. (b) Corresponding enhanced image after postprocessing. (c) Segmentation of the large
vessels. Red circles include the newly developed collateral vessels. (d) Skeletonization of large vessels to permit
calculation of total area and length. C, Quantitation of developed collaterals. Total length and area of large collateral
vessels were analyzed in the areas of femoral artery excision 20 days after single intramuscular administration of the
indicated doses of VEGF or bFGF or thrombin. Results are expressed as mean percentage change of internal control
hindlimbs of each study group  standard error (SE). Each study group included 7-8 rabbits (*P  .05).
ral ar
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arteries. Iodinated contrast (Iomeron, 400 mg iodine per
mL, Bracco, Milan, Italy) was administered through a
marginal auricular vein with an automated contrast injector
pump (total volume 10 mL, flow rate 1.0 mL/s, maximum
infusion pressure 100 psi). The localizer was placed 2 cm
below the level of the knee articulation and a dynamic
computed tomography protocol was executed with the
following parameters: scan type cine, 120 KV, 60 mAs,
rotation time 1 second, slice thickness 5 mm, table feed 15
mm, FOV small, and matrix 512. Four tissue sections, each
5 mm thick, were reconstructed with a soft tissue kernel
algorithm every 200 ms during a total scanning time of 20
seconds, after a start delay time of 5 seconds.
Images were further analyzed and postprocessed with
the Analyze PC7 software (Analyze Direct, Inc., Overland
Park, KS). A standard ROI (1 mm2) was drawn in the
center of the saphenous artery and the vessel enhancement
in Hounsfield Units (HU) was calculated in every recon-
structed image. Same areas ROIs were used in all cases for
reasons of standardization. Hence, time-resolved attenu-
ation curves of the vessel enhancement, which is represen-
tative of blood flow within the vessel, were calculated and
plotted. Peak enhancement values of the intra-arterial space
in Hounsfield units and the required time period for the
signal to reach the peak value (time-to-peak) were re-
corded. In addition, tissue perfusion analysis was per-
formed with the semiquantitative slope methodology,
which focuses in the first-pass arterial phase and avoids
re-circulation contamination.23,24 Briefly, tissue perfusion
can be calculated as the maximum slope F of the contrast
enhancement curve divided by the maximum arterial en-
hancement V:23
F
V

d
dt
[c(t)]max
a(t)max
.
Cross-sectional CT and magnetic resonance (MR)
imaging. As an adjunct to perfusion imaging, routine
contrast-enhanced cross-sectional imaging of the rabbit
hindlimbs was performed with a second infusion of iodin-
ated contrast. Scans extended from the bifurcation of the
abdominal aorta to the toes and the acquisition protocol
parameters were: scan type helical, 120 KV, 440 mAs,
rotation time 1 second, pitch 0.562, slice thickness 0.625
Table. Dose protocol of growth factors under investigatio
Agent
bFGF 1 g (n  7) 3 g (n
VEGF 1 g (n  7) 3 g (n
Thrombin 500 IU (n  7) 1500 IU (n
Normal Nonoperated normal control animals (n 
Apart from normal controls, all groups of subjects underwent bilateral femo
*Groups where CT perfusion analysis was performed.mm, FOV small, and matrix 512. Data were analyzed andboth routine axial images and reformatted multiplanar and
volume-rendered images were viewed in order to assess the
morphological architecture of the newly-developed collat-
eral networks, as previously reported.26
In order to further investigate tissue morphology and
signal intensity in the medial thigh ischemic regions, where
the angiogenic factors had been injected, subjects under-
went in vivo gadolinium-enhancedMR imaging in a clinical
1.5 Tesla MRI system (Siemens Magnetom 1.5T Vision,
SiemensHealthcare, Erlangen, Germany).MRI parameters
were as follows: maximum gradient strength 25 mTm-1,
rise time 200 s, and matrix 512 	 512. Fat-saturation
T1-weighted and T2-weighted sequences were acquired
before (TE  20 ms, TR  860 ms) and after intravenous
administration of gadolinium (TE 54 ms, TR 860 ms)
with a scan delay of 10 seconds and axial, sagittal, and
coronal sections were reconstructed and evaluated.
Histopathologic analysis. Hindlimbs of euthanized
rabbits were dissected and muscle tissue specimens were
harvested and fixed in formalin. Histopathologic analysis of
the adductor muscle in the medial thigh was performed.
Specimens were paraffin embedded and cut into 5 m
slices. Anti-CD31 immunostaining was performed for the
identification of endothelial cells and capillaries. Additional
immunostaining for specific cell markers was also per-
formed as indicated. Histologic analyses were performed in
a blinded fashion. The number of arterioles in the entire
sections were manually counted under optical microscopy
(magnification 	20) and recorded with a digital camera.
Statistical analysis. Discrete variables were expressed
as counts and percentages, while continuous variables were
given as mean standard error (SE). The unpaired Student
t test was used for testing the significance of difference of
variables that passed the normality test. Mann-Whitney test
was used for qualitative variables and for continuous vari-
ables that did not pass the normality test. Analysis if vari-
ance (ANOVA) test was employed for group comparisons
and the Tukey multiple comparison post-test was applied in
case of statistically significant differences. The threshold of
statistical significance was set at 5% (P  .05). (Graphpad
Prism 5.0; Graphpad, San Diego, Calif).
RESULTS
Thrombin stimulates arteriogenesis in the rabbit
ischemia model. Quantification of newly developed col-
Dose protocol
10 g (n  8)*
10 g (n  8)*
5000 IU (n  8)* 15,000 IU (n  8)*
tery excision.n
 7)
 7)
 7)
6)*lateral vessels was performed DSA, which is considered the
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microvessel networks.19 Focusing in particular on the mea-
surement of the arteriogenic outcome, we have segmented
and quantified the large collaterals arteries (d  500 m).
As expected in all animals, hindlimb ischemia was generally
followed by a considerable physiologic increase in muscular
capillarity (Fig 2,A and B). New collaterals originated from
the internal iliac artery (Fig 2, B, number 2) were developed
to bypass the femoral artery excision and protect the isch-
emic tissue from injury. This native arteriogenic response
was profoundly augmented by thrombin (Fig 2, B, right
hindlimb). Notably, in the representative DSA image of Fig
2, B the distal right saphenous artery (number 5) was readily
visualized compared with the control left hindlimb, which
is likely the result of the marked collateralization along the
right medial thigh and the quicker distal blood flow circu-
lation. The application of thrombin exhibited a dose-
dependent trend of arteriogenic augmentation with a sta-
tistically significant increase of 30.2%  7.4% compared
with the control hindlimb in the 5000 IU-thrombin group
(P .01, Fig 2, C). The choice of thrombin concentration
range (500 to 5000 IU) was based on its mean in vitro
effective doses multiplied by one thousand. Our aim was to
evaluate the effect of thrombin in reasonable dose range
from a clinical viewpoint. In this context, we quantified and
compared the effect of VEGF and bFGF with that of
thrombin. At doses ranging from 1 to 10 g, VEGF and
bFGF were unable to stimulate arteriogenesis in our rabbit
hindlimb ischemia model (Fig 2, C). A numerical increase
of 15.0%  10.4% was detected in the high dose group of
bFGF (10 g), which, however, was not statistically signif-
icant. Although the intramuscular application of thrombin
(5000 IU) influenced the arteriogenic response of treated
hindlimbs, the endogenous response of the contralateral
control hindlimbs was not observed to be affected. As
shown in Fig 3, A and B, the mean total collateral vessel
length and area of all (n  66) control hindlimbs were
comparable and the variation limited, indicating a local
effect of thrombin within the treated hindlimbs. However,
when thrombin was administrated (intramuscularly) in a
concentration as high as 15,000 IU, an increased arterio-
genic response was measured not only in the 15,000 IU
thrombin-treated limbs, but also in the contralateral con-
trol hindlimbs of the 15,000 IU-thrombin group (15,000
IU controls), where only normal saline had been injected.
Calculation of total collateral vessel length and area dem-
onstrated that injection of 15,000 IU of thrombin evoked
a pronounced arteriogenic outcome in both treated and
control limbs of the specific group (10,879  556 and
10,384 318 total area pixels, respectively, compared with
5882  230 of ischemic internal control limbs; P  .001),
which was equivalent to the normal femoral arterial net-
works of nonoperated animals (10,028  670) that were
included as a baseline external control group (Fig 3,A andB).
In addition, taking into consideration Hagen-Poiseuille’s law
for laminar flow conditions, which states that blood flow
within one vessel increases according to the fourth power of
the vessel diameter, we calculated the mean collateral diam-eter (defined as area/length) as a surrogate indicator of
blood hemodynamics across the newly developed collateral
networks.16 Interestingly, in both treated and control
hindlimbs of the high-dose 15,000 IU-thrombin group, a
slight but statistically significant increase of mean collateral
diameter was detected (2.75 002 and 2.77 003 pixels,
respectively) in comparison to control ischemic and other
growth factors groups, which exceeded also the mean arte-
rial diameter of nonoperated normal subjects (2.66  002
pixels; P  .01, Fig 3, C). Theoretically, even a small
change in collateral vessel diameter may reflect high
changes in blood conductance properties. In addition,
three-dimensional and multiplanar reformatted images of
cross-sectional contrast-enhanced CT visualized two dis-
tinct growth patterns of collateral networks: bridging col-
laterals interconnecting proximal and distal native arteries
and branching arteriogenesis, which are in agreement with
similar observations in rodent ischemia studies.26 Specifi-
cally, new collateral vessels originated from the internal iliac
artery and gave off multiple helical branches that connected
distally to the saphenous artery close to the knee articula-
tion (Fig 3, D).
Consistent with the angiographic analysis, histopatho-
logic analysis and CD-31 immunolocalization revealed sig-
nificantly more arterioles present in the adductor muscle of
thrombin-treated limbs (Fig 4,A). The arteriolar count per
optical field was more than double in the 5000 IU-thrombin
hindlimbs compared with the control ones (P .01), while
in bFGF- or VEGF-treated himdlimbs no significant differ-
ences were counted (Fig 4, B). In 15,000 IU-thrombin
hindlimbs, as well as in the contralateral control limbs, the
number of arterioles was significantly increased compared
with ischemic control hindlimbs (P .001) and was similar
with that observed in 5000 IU-thrombin hindlimbs (Fig 4,
B). However, further histologic examination of these mus-
cle specimens revealed abundant proliferation and infiltra-
tion of nonspecific cells. Immunoreactions for characteriza-
tion of these cells showed positive staining for PGM1 and
PK1, which are fibroblast-specific immunomarkers, and
positive for Sm-Actin, Vimentin, and S-100, which identify
differentiating monocyte cells of mesenchymal origin (Fig
4, C). These observations indicate the development of
strong inflammation reaction in the site of 15,000 IU-
thrombin administration. Similar inflammatory response
was not observed in the contralateral 15,000 IU-control
limbs, neither in the 5000 IU-thrombin groups (data not
shown). In line with these findings, contrast-enhanced CT
and MR imaging showed profoundly higher enhancement
and signal intensity only in the muscle tissues injected with
15,000 IU thrombin (Fig 5), which is in accordance with a
pronounced stimulation of soft tissue angiogenesis and
inflammation on a microscopic level.
Thrombin improves hemodynamic recovery of dis-
tal ischemic tissue. The goal of therapeutic angiogenesis
is not only to enhance ischemia-driven arteriogenesis but
also to achieve hemodynamic recovery of blood flow to the
distal ischemic tissue. Previous investigations have shown
that angiographic collateral grading does not necessarily
level
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assessed by microsphere techniques.27 Dynamic CT and
calculation of time-resolved vessel enhancement curves
provide direct in vivo functional indicators of blood flow
distal to the excised femoral artery.23,24 The evaluation
of the hemodynamic functionality of thrombin-induced
newly formed proximal collaterals was performed in a re-
gion distal to the original area of surgery and injection (Fig
2, A, white box). As shown in Fig 6, A, dynamic CT of the
saphenous artery showed a higher opacification of the right
saphenous artery (right limb; 5000 IU thrombin) com-
pared to the left one (internal control limb). The mean
absolute value of peak enhancement, which represents
Fig 3. Effects of 15,000 IU-thrombin administration in
(A) and area (B) of large collateral vessels were quantified
in normal nonoperated rabbits (normal, n 6) or control
66) or hindlimbs treated with 5000 IU-thrombin (Thr 50
(Thr 15,000 IU, n  8) or contralateral control hindl
controls, n 8). Results are expressed as mean pixel cou
.05, ***P  .001. C, Estimation of collateral diameter (
femoral artery excision area) in normal nonoperated r
IU-thrombin (Thr 15,000 IU, n  8) or contralateral
(15,000 IU controls, n  8). Results are expressed as
reconstruction of CT angiogram of bilateral hindlimbs
denote the internal iliac arteries from where helical bra
arteries reconstitute through collateral blood flow at theblood-contrast concentration and is proportional to thearterial blood flow, showed a 100.9%  40.9% increase
(P  .05) in the hindlimbs that had received 5000 IU of
thrombin in comparison to the contralateral control hind-
limbs (Fig 6, B, left panel). An increase of almost 50% was
also observed in the high-dose (10 g) groups of VEGF
and bFGF (Fig 6, B, left panel). However, neither of these
differences proved to be statistically significant. In addition,
the mean time-to-peak enhancement was measured to be
shorter for both thrombin (5000 IU) and bFGF (10 g)
groups, indicating a quicker blood flow circulation (Fig 6,
B, right panel). However, only for the thrombin group was
this difference statistically significant (P  .05). The time-
resolved plots of saphenous artery enhancement portray
it ischemia arteriogenic response. A and B, Total length
n the regions of interest (the femoral artery excision area)
mic hindlimbs of all treatment groups (control limbs, n
, n 7) or hindlimbs treated with 15,000 IU-thrombin
of the 15,000 IU-thrombin treated limbs (15,000 IU
ach pixel is equal to approximately 200 m) SE. *P 
tio of vessel area to length) in the regions-of-interest (the
s (normal, n  6) or hindlimbs treated with 15,000
ol hindlimbs of the 15,000 IU-thrombin treated limbs
pixel counts  SE. *P  .05. D, Three-dimensional
e 40th postsurgical day (posterior view). White asterisks
g collaterals originate (double white arrow). Saphenous
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nchinfurther the differences observed in the dynamics of blood
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growth factors (Fig 6, C). Interestingly, attenuation curves
of thrombin treated limbs exhibited delayed but eminently
higher enhancement than normal limbs, which likely re-
flects the more time-consuming circulation of higher blood
volume through the more extensive collateralization stim-
ulated by thrombin. These observations provide evidence
that blood circulation through the newly developed collat-eral networks is more delayed compared to normal femoral
arteries regardless of the growth factor applied and its
arteriogenic outcome.
In line with the quantitative angiographic data, in-
creased higher saphenous artery enhancement was docu-
mented both in the treated and control hindlimbs of the
15,000 IU-thrombin-treated animals (data not shown).
Again, the absolute value of peak enhancement expressed in
Hounsfield units, showed a 70% to 80% increase in the
ischemic limbs injected with 15,000 IU of thrombin, as
well as in the 15,000 IU control hindlimbs compared with
normal subjects (Fig 6,D), while the time-to-peak intervals
were significantly delayed (P  .001, Fig 6, E), suggesting
that circulation dynamics are delayed due to the longer and
tortuous collateral routes that blood has to travel in order
to bypass the occluded native artery.
To further elucidate overall collateral blood conduc-
tance, we applied the slope method score, which is a semi-
quantitative surrogate endpoint of distal tissue blood per-
fusion.24 Analysis of the dynamic CT data with the slope
method showed a significant decrease of limb perfusion in
the case of the ischemic control (5.0  0.3) and both
VEGF (4.8  0.2) and bFGF (4.5  0.2) 10 g groups
(P  .01, Fig 6, F). Remarkably, however, there was no
significant inferiority of the 5000 IU (5.7  0.3) and
15,000 IU (5.4 0.6) thrombin-treated limbs vs the score
of normal rabbits (6.5  0.3; Fig 6, F), suggesting a trend
towards hemodynamic recovery and normalization of distal
limb perfusion. Of interest, the same normalization of
perfusion score was noted in the control limbs of the
15,000 IU thrombin group (5.6  0.4), which is in line
with the increased arteriogenic outcome documented an-
giographically, pointing to a considerable systemic effect of
thrombin in the reperfusion of the contralateral control
ischemic limbs. Almost all study subjects exhibited exten-
sive hair loss and ischemic ulcers along the tibia and the
feet, most of which demonstrated improved or complete
Fig 4. Histopathologic analysis. A, Immunolocalization of arte-
rioles. Anti-CD31 staining of histologic sections of ischemic hind-
limbs adductor muscle tissue 20 days after treatment with saline
(control ischemic hindlimbs) or the indicated doses of VEGF or bFGF
or thrombin (Thr). Representative photos are shown (Original mag-
nification	20; black arrows point to arterioles).B,Count of arterioles
per optical field. Stained vessels were counted in the histologic sec-
tions of control ischemic hindlimbs (control limbs) or of hindlimbs
treated with indicated doses of VEGF, bFGF, and thrombin (Thr)
or the contralateral control hindlimbs of the 15,000 IU-thrombin
treated limbs (15,000 IU controls). Results are expressed as mean
arteriolar count  SE. *P  .05. C,Hematoxylin-eosin (left image)
and positive PGM1 immunostaining (right image) of adductor mus-
cle specimens treated with 15,000 IU thrombin. Note the abundant
proliferation and infiltration of nonspecific cells (magnification	40).
Immunoreactions of these cells were positive for PGM1 and PK1
(fibroblast-specific immunomarkers) and also positive for Sm-Actin,
Vimentin, and S100 (relating to differentiating monocyte cells of mes-
enchymal origin, data not shown).
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However, no significant differences in comparison to
groups with other growth factors or ischemic control limbs
were noted (data not shown).
DISCUSSION
In this study, using a rabbit hindlimb ischemic model,
we have shown that a single intramuscular injection of
thrombin can enhance the angiogenic response to ischemia
with a significant increase of regional collateralization and
enhanced distal blood flow circulation. Based on the in-
creased collateral area and length and the improved indices
of tissue blood perfusion, thrombin treatment resulted in
both angiographically and functionally better vasculature.
Our findings further extend previous reports indicating that
thrombin functions as a potent proangiogenic molecule.
For instance, the ability of thrombin to stimulate the for-
mation of vessels has been evidenced in the chick cho-
rioallantoic membrane (CAM) system7 and the matrigel in
vivo model.28 Furthermore, Dimitropoulou et al29 have
Fig 5. Cross-sectional CT and MR of 15,000 IU-thro
parasagittal (right panel) maximum intensity projection
after single intramuscular injection of 15,000 IU of throm
postgadolinium injection (right panel) of rabbits 20 day
thrombin. Note the higher enhancement and signal inte
arrows).shown that thrombin significantly increased not only thenumber of vessel in CAM but also their diameters and
lengths.
The principal goal of therapeutic angiogenesis is to
develop collateral vessels that can restore sufficient blood
flow in ischemic tissue.30 Past studies for therapeutic angio-
genesis sought to improve tissue perfusion through the
delivery of angiogenic factors and cytokines such as bFGF,
VEGF, or platelet-derived growth factor BB (PDGF-BB).
However, single administration of these factors was found
to be insufficient to establish stable vascular networks. Even
if a single growth factor can initiate angiogenesis, it is
becoming increasingly apparent that other cooperating fac-
tors and receptor-mediating mechanisms are required at
later stages for the development of mature vascular net-
works.31 Therefore, several reports have suggested the
impact of combination of growth factors for therapeutic
angiogenesis. For instance, the combination of bFGF and
PDGF-BB synergistically induced vascular networks that
remained stable for more than a year, even after the angio-
genic factors were depleted.32 In this regard, thrombin
treated rabbits. A, Representative axial (left panel) and
) contrast-enhanced CT images of rabbit limbs 20 days
B, Representative axial MR images pre- (left panel) and
single intramuscular administration with 15,000 IU of
of the muscle injected with 15,000 IU thrombin (whitembin
(MIP
bin.
s after
nsitythrough its multiplicity of effects on angiogenesis, survival,
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tomography of rabbit saphenous arteries 20 days after administration of 5000 IU-thrombin (right limb). Top baseline
cross-sectional image at a distal level below-the-knee before infusion of iodinated contrast from a marginal auricular vein. A
region-of-interest was setwithin the intravascular space of the saphenous artery (bright vessels within the red and yellow circles).
Intermediate image after contrast infusion and arrival of contrast shows peak enhancement of the arteries. The bright
enhancement within the arteries corresponds to the circulating blood volume. Bottom final image after digital subtraction of
the above. B, Perfusion analysis of dynamic-CT study. Peak vessel enhancement (left panel) and the corresponding
time-to-peak intervals (right panel) were calculated in the regions of saphenous arteries 20 days after single intramuscular
administration of the indicated doses of VEGF or bFGF or thrombin. Results expressed as mean percentage change in
comparison to internal control hindlimbs of each study group  SE. Each study group included seven to eight rabbits.
*P .05.C,Average time-resolved curves of saphenous artery enhancementwere calculated in normal nonoperated hindlimbs
(normal, n  6) or total control ischemic hindlimbs (control limbs, n  66) or hindlimbs treated with indicated doses of
thrombin (n 7) or VEGF (n 8) or bFGF (n 8) or contralateral control hindlimbs of the 15,000 IU-thrombin treated
limbs (15,000 IU controls, n  8). Results expressed as mean Hounsfield Units  SE. D and E, Dynamic CT perfusion
analysis of 15,000 IU-thrombin treated rabbits. Peak vessel enhancement (D) and the corresponding time-to-peak
enhancement (E) were calculated in the regions of saphenous arteries 20 days after single intramuscular administration of
15,000 IU thrombin. Results expressed as meanHounsfield Units SE (left panel) or as mean seconds SE (right panel).
***P .001. F, Semiquantitative perfusion score calculated with the slope method.24 *P .05.
JOURNAL OF VASCULAR SURGERY
April 20091010 Katsanos et alinteraction with other growth factors, and many cell types,
may have the unique ability to orchestrate the requirements
for the development of mature blood vessels. Although a
long-term study of thrombin-induced neovascularization
has not yet been accomplished, the high vessel maturity
observed here might be a promising sign for long duration
of their functionality.
The mechanism underlying the arteriogenic effect in-
duced by thrombinmay be complex. A possible physiologic
role of PAR1 in the reparative processes that result in tissue
recovery is under investigation determining the protein and
mRNA levels in ischemic adductor muscles and examining
the effect of specific exogenous PAR1 activators. However,
several aspects can be considered by previous studies. It is
now recognized that thrombin is able to influence angiogen-
esis through both coagulation-dependent and coagulation-
independent mechanisms. The coagulation-dependent
pathways involve platelet activation and fibrin formation.
Vessel wall injury or thrombus formation stimulates platelet
to adhere to subendothelial matrix and to undergo activa-
tion by thrombin, leading to aggregation and degranula-
tion. It should be emphasized that platelet -granules
are the source of a plethora of proangiogenic factors, in-
cluding VEGF, bFGF, and PDGF-BB,33,34 and the ab-
sence of platelets inhibits the early stages of angiogenesis
and contributes to the formation of decreased number of
new vessels in vivo.35,36 In addition, fibrin networks, gen-
erated by thrombin in the local microenvironment of
wound healing, inflammation, or malignant tumor growth,
exert a supportive role for endothelial cell adhesion, sur-
vival, and angiogenesis.37,38 Fibrin also provides storage of
proangiogenic growth factors, such as bFGF, and VEGF as
well as thrombin itself, which are protected from proteo-
lytic degradation and released by proteolytic enzymes, gen-
erated during invasion by endothelial cells. These reports
are in line and explain the observations by other investiga-
tors, who have shown that the use of anticoagulant drugs
after induction of tissue ischemia hampered spontaneous
arteriogenic response in a rodent hindlimb ischemia
model.39 Accordingly, intramuscular injection of fibrin
matrices promoted arteriogenesis in a rabbit hindlimb
ischemia model.40
On the other hand, many cellular actions of thrombin
are regulated by mechanisms apart from its role in coagu-
lation cascade. Thrombin is clearly accepted as the principal
physiologic regulator of PAR1 and PAR4,41 particularly in
terms of targeting the cardiovascular system and inflamma-
tion, which is an early key process for ischemia-induced
angiogenesis and arteriogenesis.42 In this regard, many
studies showed that thrombin and its receptors exist not
only in the vascular wall and cells but also in immune-
privileged tissues and cells, which play important proin-
flammatory roles. Indeed, PAR1 expression has been found
on many immune cells, including macrophages, mono-
cytes, lymphocytes, and mast cells, and PAR4 appears to
play a key role in thrombin-regulated leukocyte rolling and
adherence.43 Consequently, amassed data have docu-
mented the ability of thrombin to trigger many of theresponses associated with inflammation, including endo-
thelial cell activation (P-selectin display, increased adhesion
of leukocytes and platelets), along with increased vascular
permeability, mast cell degranulation, increased adhesion
of neutrophils to the endothelium, platelet aggregation and
chemotaxis of neutrophils, and the induction of cytokine
release from epithelial and vascular smooth muscle and
endothelial cells. Furthermore, thrombin acting through
PAR1 has been shown to play an essential role in the
generation of monocyte chemoattractant protein, which is
a key molecule for the recruitment of monocytes and
macrophages.44 The important role of thrombin in initiat-
ing inflammatory responses provides a plausible explana-
tion for the profound inflammatory reactions observed in
those limbs receiving the highest dose (15,000 IU) of
thrombin. At concentrations of thrombin up to 5000 IU,
we found no evidence of focal inflammation, which may
due to the fact that the inflammation reactions induced by
thrombin were not that significant to cause a marked
change in histology. However, it is likely that high concen-
trations of thrombin may mount a more robust reparative
response by amplifying proinflammatory mechanisms im-
plicated in angiogenesis.
There are several limitations in our study. First, we
investigated arteriogenesis in the specific time-point of the
40th postsurgical day, 20 days after injection of thrombin.
Althoughmany investigators have followed this protocol, it
is likely that the long 20-day postsurgery period masks part
of the arteriogenic effect of thrombin. On the other hand,
therapeutic angiogenesis in ischemia will be effective only if
stable arteries can be developed. Taking into consideration
that new collateral vessels require up to 20 days following
the ischemic insult to fully develop, it is possible that
repeated multiple injections of smaller doses or sustained
release of thrombin from biodegradable systems would be
better than bolus injection of high doses. Nonetheless,
additional experiments have been designed to further in-
vestigate the time-dependence and dose-fractionation of
thrombin-induced functional arteriogenesis. Second, the
inability of VEGF and bFGF to stimulate arteriogenesis was
likely due to the relative low doses used in our model.
However, the aim of our comparative experiments was to
evaluate the effect of thrombin, bFGF, and VEGF in rea-
sonable dose ranges from a clinical viewpoint. As men-
tioned before, the range of concentrations used was based
on their mean in vitro effective doses multiplied by one
thousand. Third, we did not perform blood biochemistry
tests to detect systemic circulation of thrombin or any
alterations in blood coagulation parameters; neither did we
evaluate the subjects for any ectopic thrombin activity like
formation of venous clot or emboli. Although systemic
VEGF and bFGF levels can be measured using elaborate
high-affinity antagonist antibody assays, plasma thrombin is
rapidly deactivated and can only be assayed indirectly from
the levels of circulating fibrinopeptide A.45 Such tests may
be important since injection of 15,000 IU of thrombin
exerted a pronounced arteriogenic effect also in the con-
tralateral control limbs, which implies that there are sys-
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stances, a fractionated protocol of thrombin injection may
readily achieve enhanced collateral augmentation whilst
avoiding any potential toxicity or adverse effects from in-
creased plasma levels.
CONCLUSION
The present study provides the first evidence of an
arteriogenic role for thrombin. Thrombin improved limb
ischemia in rabbits by promoting collateral vessel develop-
ment and recovery of ischemic tissue perfusion. This is an
exciting prospect and presents a challenge to both clinicians
and basic scientists for understanding the role of thrombin
in peripheral arterial disease.
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